Business Wire

CA-VELODYNE-LIDAR

30.7.2020 14:02:16 CEST | Business Wire | Press release

Share
Velodyne Lidar Sensors Power Emesent’s Hovermap to Fly Beyond the Visual Line of Sight

Velodyne Lidar, Inc. today announced that Emesent’s newly introduced Autonomy Level 2 (AL2) technology for Hovermap uses Velodyne lidar sensors to provide real-time perception and high-quality, accurate 3D data. Hovermap is a plug-and-play mapping and autonomy payload for industrial drones that enables autonomous flight in areas beyond visual line of sight (BVLOS) and without GPS connectivity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200730005182/en/

The AL2 technology uses Velodyne’s Puck LITE lidar as the primary perception and mapping sensor. This allows autonomous exploration, navigation and lidar mapping in challenging inaccessible environments such as mines, civil construction works, telecommunications infrastructure and disaster response environments. As part of Emesent’s simultaneous localization and mapping (SLAM) based autonomy stack, AL2 powers drones to fly beyond communications range, self-navigate and avoid obstacles including thin wires and branches.

AL2 can be operated from take-off to landing by setting smart waypoints in a live 3D map streamed to a tablet. This allows operators to remain a safe distance from hazardous environments such as brows, stope edges, confined spaces and heights. The rich data from the Puck LITE sensor enables companies to gain better data insights on how to make mines and other environments safe.

“The Velodyne Puck LITE is simply a sensational sensor for creating drone-based mapping and autonomy solutions because of its compact size, light weight and performance – all critical for drone-mounted systems,” said Dr. Stefan Hrabar, Emesent CEO. “The sensor was an essential ingredient in helping us to create game-changing new technology that can obtain vital data in challenging environments in real time without risking the machine or operator safety.”

Emesent is an Automated with Velodyne partner at the forefront of GPS-denied drone autonomy. The company recently placed fourth in the urban circuit of the DARPA Subterranean (“SubT”) Challenge together with the Robotics and Autonomous Systems Group at the Commonwealth Scientific and Industrial Research Organization (CSIRO) and Georgia Institute of Technology.

“Emesent’s innovative use of Velodyne’s lidar sensors is helping to deliver valuable data and insights that were previously impossible to access,” said Jon Barad, Vice President of Business Development, Velodyne Lidar. “In addition to what they provide today to the mining, infrastructure, survey and mapping industries, it is exciting to consider how this innovation will help usher in a new era of autonomous drone operation across a variety of other industries.”

In the United States, the Federal Aviation Administration (FAA) currently has restrictions on drones flying beyond the visual line of sight. Emesent’s technology innovation could potentially usher in a new era of safe, autonomous drone flight – not only in mines but everywhere.

Velodyne Puck LITE sensors deliver a high-resolution image to measure and analyze indoor and outdoor environments. Designed for applications that require a sensor with a low weight and compact size, the Puck LITE delivers outstanding resolution and performance for mobile and UAV/drone applications. It provides a full 360-degree environmental view to deliver real-time 3D data.

About Velodyne Lidar

Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.

About Emesent

Emesent is a world-leader in drone autonomy, lidar mapping and data analytics. Founded in 2018, Emesent has since built a reputation for delivering high-quality data capture in the mining, infrastructure, survey and mapping industries. Their flagship product, Hovermap, is a smart mobile scanning unit that combines advanced collision avoidance and autonomous flight technologies to map hazardous and GPS-denied environments. Hovermap is uniquely versatile, it can be handheld, drone- or vehicle-mounted to map challenging, inaccessible areas. With a wide range of applications, Hovermap is being used by customers around the world.

Link:

ClickThru

Social Media:

https://www.facebook.com/velodyneLiDAR/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye